109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Wound healing compositions and treatments
#3302Saccharide-modified nucleic acid molecules
#3303NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#3304METHODS
#3305Cardiac myofibril induction
#3306Treatment of ocular disorders with anti-connexin proteins and mimetics
#3307Molecular targets for healing or treating wounds
#3308Methods and compositions for weed control
#3309Methods and compositions for weed control
#3310Modulation of synaptic maintenance
#3311Compositions and methods for treatment of prostate and other cancers
#3312Recurrent gene fusions in prostate cancer
#3313Sequence-specific inhibition of small RNA function
#3314DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF
#3315Methods of determining eosinophilic gastritis status based on marker or gene expression
#3316Modulators of intracellular chloride concentration for treating down syndrome
#3317SYSTEM FOR CO-DELIVERY OF POLYNUCLEOTIDES AND DRUGS INTO PROTEASE-EXPRESSING CELLS
#3318Modulation of huntingtin expression
#3319Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof
#3320Liposomal particles, methods of making same and uses thereof
#3321Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
#3322DDR1 ANTAGONIST OR AN INHIBITOR OF DDR1 GENE EXPRESSION FOR USE IN THE PREVENTION OR TREATMENT OF CRESCENTIC GLOMERULONEPHRITIS
#3323Double-stranded RNA compounds to CASP2 and uses thereof
#3324COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#3325Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#3326Compositions for modulating C9ORF72 expression
#3327Targeted augmentation of nuclear gene output
#3328C/EBPα short activating RNA compositions and methods of use
#3329EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#3330Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1
#3331METHOD FOR TRANSFORMATION OF STRAMENOPILE
#3332APOB Antisense Conjugate Compounds
#3333GENES OF AN OTITIS MEDIA ISOLATE OF NONTYPEABLE HEAMOPHILUS INFLUENZAE
#3334Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#3335WHEAT WITH INCREASED NUMBER OF GRAINS AND METHOD FOR PRODUCING THE SAME, AND AGENT FOR INCREASING THE NUMBER OF WHEAT GRAINS
#3336Antisense composition and method for treating muscle atrophy
#3337PREVENTION OF VIRAL INFECTIVITY
#3338Modulation of T cell signaling threshold and T cell sensitivity to antigens
#3339BIOMARKERS FOR THE DIAGNOSIS OF INTERSTITIAL CYSTITIS
#3340Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3
#3341DNMT inhibitors
#3342Compositions and methods for inhibiting JC virus (JCV)
#3343COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGIC CELL DEATH
#3344Nucleic acid silencing sequences
#3345IMPROVED WOUND HEALING COMPOSITIONS AND TREATMENTS
#3346Dynamin 2 inhibitor for the treatment of centronuclear myopathies
#3347COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION
#3348MODIFIED iRNA AGENTS
#3349OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#3350Suicide contrast agents targeting HIV reservoirs for theranostic eradication
#3351MCPIP protection against osteoclast production
#3352COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#3353Identification of structurally similar small molecules that enhance therapeutic exon skipping
#3354Block copolymers and uses thereof
#3355MicroRNA PROFILES IN HEART FAILURE: METHODS AND SYSTEMS FOR DETECTION AND USE
#3356MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#3357MicroRNA compounds and methods for modulating miR-122
#3358MicroRNAs modulating the effect of glucocorticoid signaling
#3359Compositions for modulating C9ORF72 expression
#3360Compositions for inhibiting checkpoint gene expression and uses thereof
#3361Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#3362Method for reducing circulating leukocytes in a human subject
#3363Antisense compounds targeting genes associated with cystic fibrosis
#3364Reducing intron retention
#3365Microrna inhibition for the treatment of inflammation and myeloproliferative disorders
#3366MicroRNA compounds and methods for modulating miR-21 activity
#3367HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
#3368Modeling and Predicting Differential Alternative Splicing Events and Applications Thereof
#3369Modulation of apolipoprotein C-III expression
#3370Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
#3371Compounds for inducing anti-tumor immunity and methods thereof
#3372Tau antisense oligomers and uses thereof
#3373Peptide oligonucleotide conjugates
#3374Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
#3375TOLEROGENIC DENDRITIC CELLS TO TREAT INFLAMMATORY BOWEL DISEASE
#3376Hypoxia-Targeted Delivery System for Pharmaceutical Agents
#3377Compositions and methods for treating amyotrophic lateral sclerosis
#3378Methods and pharmaceutical compositions for treatment of cystic fibrosis
#3379MODULATORS OF COMPLEMENT FACTOR B
#3380Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
#3381Antisense compositions and methods of making and using same
#3382NOVEL LINCRNA AND INTERFERING NUCLEIC ACID MOLECULES, COMPOSITIONS AND METHODS AND USES THEREOF FOR REGULATING ANGIOGENESIS AND RELATED CONDITIONS
#3383Nucleic acids and methods for the treatment of Pompe disease
#3384Compositions and methods for treating lung disease and injury
#3385Genetic inhibition by double-stranded RNA
#3386Antisense Oligonucleotides Against Neutral Sphingomyelinase and Neutral Sphingomyelinase Inhibitor GW4869 for Degenerative Neurological Disorders
#3387Antisense-induced exon2 inclusion in acid alpha-glucosidase
#3388Neurocalcin delta inhibitors and therapeutic and non-therapeutic uses thereof
#3389Nanocomplexes for co-delivering a drug and siRNA and uses thereof
#3390Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
#3391Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA
#3392SPARC (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
#3393METHODS OF MODULATING THE NEGATIVE CHEMOTAXIS OF IMMUNE CELLS
#3394Ligase E3 RNF185 inhibitors and uses thereof
#3395Methods of identifying and treating poor prognosis cancers
#3396Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#3397Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#3398MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#3399Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
#3400REDUCING NONSENSE-MEDIATED MRNA DECAY
#3401Compositions and methods for modulating angiopoietin-like 3 expression
#3402Antisense oligonucleotides with improved pharmacokinetic properties
#3403Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#3404Composition for reducing senescence of cell or subject comprising smurf2 inhibitor and use thereof
#3405Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#3406Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
#3407C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
#3408Effective method for specific gene silencing using artificial small RNA
#3409Treating alcohol-mediated disorders by inhibition of RGS6
#3410Anticancer combinations
#3411Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#3412Antisense molecules and methods for treating pathologies
#3413Channel modulators
#3414Antisense molecules for treatment of infection
#3415Sphingolipid-polyalkylamine-oligonucleotide compounds
#3416Methods of treating pre-eclampsia or eclampsia
#3417Clusterin Antisense Therapy for Treatment of Cancer
#3418ANTISENSE DESIGN
#3419ANTISENSE DESIGN
#3420TREATMENT OF INSULIN GENE (INS) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN INSULIN GENE (INS)
#3421MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#3422Methods for suppressing adipocyte differentiation
#3423COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING MUSCULAR DYSTROPHY
#3424Formulations comprising antisense nucleotides to connexins
#3425Methods and compounds useful in conditions related to repeat expansion
#3426BGL6 beta-glucosidase and nucleic acids encoding the same
#3427METHODS AND MATERIALS FOR TREATING CANCER
#3428Antisense oligonucleotide compositions
#3429Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
#3430METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST
#3431Methods and compositions involving lincRNA and leukemia
#3432TMPRSS6 iRNA compositions and methods of use thereof
#3433Oligomers with improved off-target profile
#3434Compositions for modulating Tau expression
#3435Antisense-oligonucleotides as inhibitors of TGF-R signaling
#3436Oligonucleotide conjugates
#3437Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#3438Microrna compounds and methods for modulating MIR-21 activity
#3439ANTISENSE COMPOUNDS AND USES THEREOF
#3440Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3441Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3442Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3443Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
#3444Double-stranded antisense nucleic acid with exon-skipping effect
#3445OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF
#3446Oligonucleotide analogues incorporating 5-aza-cytosine therein
#3447Compounds and methods for trans-membrane delivery of molecules
#3448Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms
#3449Autoimmune disease treatments
#3450Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
#3451COMPOSITIONS AND METHODS FOR MODULATING FOXP3 EXPRESSION
#3452Dosages and methods for delivering lipid formulated nucleic acid molecules
#3453SiRNA targeting HSR1
#3454Molecules of the card-related protein family and uses thereof
#3455TRICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
#3456Methods and compositions for mobilizing stem cells
#3457In vitro method of inhibiting the growth of radioresistant laryngeal cancer cells
#3458Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
#3459PROSTATE CANCER-SPECIFIC ALTERATIONS IN ERG GENE EXPRESSION AND DETECTION AND TREATMENT METHODS BASED ON THOSE ALTERATIONS
#3460Methods and compositions for the treatment of cancer
#3461Dermatological, pharmaceutical composition suitable for oligonucleotides
#3462Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases
#3463Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)
#3464Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
#3465Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
#3466Modulation of HSP47 expression
#3467Hydrophobically modified antisense oligonucleotides comprising a ketal group
#3468OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE
#3469CHIMERIC SINGLE-STRANDED ANTISENSE POLYNUCLEOTIDES AND DOUBLE-STRANDED ANTISENSE AGENT
#3470Antisense antibacterial compounds and methods
#3471Compositions and methods for inhibiting expression of the HAMP gene
#3472Protection against ionizing radiation and chemotherapy toxicity via latexin regulation
#3473miR-96-5p INHIBITOR AND A SCREENING METHOD FOR THE INHIBITOR
#3474Oligonucleotide analogues targeting human LMNA
#3475CROSSLINKED ANTI-HIV-1 COMPOSITIONS FOR POTENT AND BROAD NEUTRALIZATION
#3476Recurrent gene fusions in prostate cancer
#3477QSOX1 as an anti-neoplastic drug target
#3478Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
#3479Antisense compounds and uses thereof
#3480Compositions and methods for modulating apolipoprotein (a) expression
#3481Compositions and methods for modulating apolipoprotein C-III expression
#3482Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease
#3483Methods and compositions for stimulating reepithelialisation during wound healing
#3484Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#3485Modified TGF-beta oligonucleotides
#3486Morpholino oligonucleotide manufacturing method
#3487Compositions and methods
#3488Compositions and methods for modulating HBV expression
#3489Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
#3490Compositions and methods for modulation nucleic acids through nonsense mediated decay
#3491Modulation of androgen receptor expression
#3492Modulation of dystrophia myotonica-protein kinase (DMPK) expression
#3493SMN2 element 1 antisense compositions and methods and uses thereof
#3494Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage
#3495Polynucleotides and polypeptide sequences involved in the process of bone remodeling
#3496BIOACTIVE APOLAR EXTRACT CONTAINING PLANT GENETIC MATERIAL FOR TREATMENT OF MAMMALIAN DISEASES
#3497Modified TGF-beta2 oligonucleotides
#3498MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#3499MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#3500Compositions and methods for reducing neointima formation
#3501Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
#3502Biocompatible infinite coordination polymer nanoparticle-nucleic acid conjugates for antisense gene regulation
#3503COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#3504Treatment of genetic disorders associated with DNA repeat instability
#3505METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN
#3506Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
#3507B7-H4 EXPRESSION ON TUMOR VASCULATURE
#3508METHODS TO OBTAIN A NOVEL CLASS OF GRAM NEGATIVE BACTERIA ANTIBIOTICS WHICH TARGET AN UNKNOWN CELL DIVISION ASSOCIATED PROTEIN LOP1
#3509Materials and Methods Useful For Affecting Tumor Cell Growth, Migration and Invasion
#3510Modulation of hepatitis B virus (HBV) expression
#3511Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
#3512Signal activated RNA interference
#3513Site-specific induction of bimolecular quadruplex-duplex hybrids and methods of using the same
#3514ApoIII and the Treatment and Diagnosis of Diabetes
#3515Morpholinos, morpholino upregulating, and associated methods
#3516Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient
#3517Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#3518Oligonucleotides for modulating gene expression and uses thereof
#3519EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#3520In vivo delivery of oligonucleotides
#3521Modulation of RNA activity and vascular permeability
#3522FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION FOR THE TREATMENT OF DISEASE
#3523Combination therapy for MDS
#3524Aptamer-guided gene targeting
#3525Oral delivery of therapeutically effective LNA oligonucleotides
#3526Inhibitors of MYH7B and uses thereof
#3527Compositions and methods for modulating Tau expression
#3528Methods for Promoting Reinnervation of Auditory Hair Cells
#3529Treatment of staphylococcal disorders
#3530Therapeutic agent for fibroid lung
#3531FALZ for use as a target for therapies to treat cancer
#3532Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT
#3533Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
#3534Oligomers
#3535Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
#3536Methods for monitoring C9ORF72 expression
#3537LNA antisense oligonucleotides for the modulation of Myc expression
#3538Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3539PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS (PMOS) AND THEIR USE IN SUPPRESSION OF MUTANT HUNTINGTIN EXPRESSION AND ATTENUATION OF NEUROTOXICITY
#3540Lipohillic oligonucleotide analogs
#3541CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#3542Reducing intron retention
#3543Selective targeting of cancer stem cells
#3544Lipid-Coated Albumin Nanoparticle Compositions and Methods of Making and Method of Using the Same
#3545Oligomers and oligomer conjugates
#3546Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
#3547OLIGOMERIC COMPOUNDS AND EXCIPIENTS
#3548METHODS FOR REGULATING HAIR GROWTH DISORDERS
#3549Vectors and methods for genetic immunization
#3550Cell-penetrating oligonucleotides
#3551Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#3552RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
#3553Multiple exon skipping compositions for DMD
#3554ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
#3555ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#3556Multiple exon skipping compositions for DMD
#3557Multiple exon skipping compositions for DMD
#3558Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#3559Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#3560Compositions and methods for modulation of SMN2 splicing in a subject
#3561Cancer treatment
#3562ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS
#3563Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
#3564Selective antisense compounds and uses thereof
#3565Modified oligonucleotides for telomerase inhibition
#3566Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#3567Multiple exon skipping compositions for DMD
#3568Multiple exon skipping compositions for DMD
#3569Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#3570Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#3571Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
#3572METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
#3573Treatment of metastatic tumors
#3574Composition for gene delivery comprising chitosan and liquid crystal formation material
#3575Process for formulating an anionic agent
#3576Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors
#3577ANTISENSE MODULATION OF NUCLEAR HORMONE RECEPTORS
#3578Treatment of neuropathic pain
#3579Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
#3580Compositions and methods for treating pancreatic cancer
#3581TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1
#3582LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
#3583Methods to screen compounds for regulating USF1 activity and methods and compounds to treat cardiometabolic and lipid pathologies
#3584Methods of treating cholangiocarcinoma
#3585Methods for treating eye disorders
#3586EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#3587Antisense antibacterial compounds and methods
#3588INDUCTION OF EXON SKIPPING IN EUKARYOTIC CELLS
#3589INHIBITION OF THE COMPLEMENT SYSTEM
#3590Cancer antigen EEF2
#3591Fertility gene and use thereof
#3592Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#3593Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
#3594COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#3595Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof
#3596METHOD OF TREATING DELAYED HEALING OF A WOUND ASSOCIATED WITH DIABETES
#3597DIAGNOSTIC MARKERS FOR TREATING CELL PROLIFERATIVE DISORDERS WITH TELOMERASE INHIBITORS
#3598METHODS FOR CONTROLLING STEM CELL DIFFERENTIATION
#3599Vectors and methods for genetic immunization
#3600Modulation of Insulin Like Growth Factor I Receptor Expression in Cancer